Novocell Renamed ViaCyte; Gets 3 Patents

Xconomy San Diego — 

San Diego-based Novocell, Inc., a preclinical stem cell engineering company focused on diabetes, has changed its name to ViaCyte, according to an announcement. In a separate statement, the company says it also recently obtained three additional U.S. patents. The new patents cover methods for increasing definitive endoderm production, methods of producing pancreatic hormones, and a method of producing definitive endoderm that the company says has been widely adopted in the field.